GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Sartorius AG (CHIX:SRT3d) » Definitions » Margin of Safety % (DCF FCF Based)

Sartorius AG (CHIX:SRT3D) Margin of Safety % (DCF FCF Based) : 13.30% (As of Dec. 14, 2024)


View and export this data going back to 2012. Start your Free Trial

What is Sartorius AG Margin of Safety % (DCF FCF Based)?

Margin of Safety % (DCF FCF Based) = (Intrinsic Value: DCF (FCF Based) - Current Price) / Intrinsic Value: DCF (FCF Based).

Note: Discounted FCF model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

As of today (2024-12-14), Sartorius AG's Predictability Rank is 3-Stars. Sartorius AG's intrinsic value calculated from the Discounted FCF model is €113.34 and current share price is €227.90. Consequently,

Sartorius AG's Margin of Safety % (DCF FCF Based) using Discounted FCF model is 13.30%.

Competitive Comparison of Sartorius AG's Margin of Safety % (DCF FCF Based)

For the Medical Instruments & Supplies subindustry, Sartorius AG's Margin of Safety % (DCF FCF Based), along with its competitors' market caps and Margin of Safety % (DCF FCF Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sartorius AG's Margin of Safety % (DCF FCF Based) Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Sartorius AG's Margin of Safety % (DCF FCF Based) distribution charts can be found below:

* The bar in red indicates where Sartorius AG's Margin of Safety % (DCF FCF Based) falls into.


Sartorius AG Margin of Safety % (DCF FCF Based) Calculation

Sartorius AG's Margin of Safety % (DCF FCF Based) for today is calculated as

Margin of Safety % (DCF FCF Based)=(Intrinsic Value: DCF (FCF Based)-Current Price)/Intrinsic Value: DCF (FCF Based)
=(262.87-227.90)/262.87
=13.30 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The intrinsic value is calculated from the Discounted FCF model with default parameters. The calculation method is the same as Discounted Earnings model except free cash flow are used in the calculation instead of earnings per share.

Sartorius AG Margin of Safety % (DCF FCF Based) Related Terms

Thank you for viewing the detailed overview of Sartorius AG's Margin of Safety % (DCF FCF Based) provided by GuruFocus.com. Please click on the following links to see related term pages.

Sartorius AG Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Sartorius AG (CHIX:SRT3d) » Definitions » Margin of Safety % (DCF FCF Based)
Comparable Companies
LSE:CTEC LSE:AMS LSE:TSTL LSE:BVC LSE:SPEC LSE:CNSL ISRG XPAR:EL BDX TSE:7741 XSWX:ALC RMD TSE:4543 OCSE:COLO B WST COO XSWX:STMN HOLX TSE:7733 XPAR:DIM
Traded in Other Exchanges
SOAGY:USA SSSGY:USA SUVPF:USA SARTF:USA 1SRT:Italy 1SRT3:Italy 0NIR:UK 0NIQ:UK SRT3:Germany SRT3:Bulgaria
Address
Otto-Brenner-Strasse 20, Gottingen, NI, DEU, 37079
Website
https://www.sartorius.com
Sartorius AG is a leading provider of bioprocessing solutions. Its Bioprocess division sells equipment and consumables for upstream and downstream manufacturing of biologic drugs, and has a focus on single-use technology, or SUT. Its Lab Products and Services division offers a wide range of products for lab use, including scales, pipettes, and filtration equipment. As of 2022, the Bioprocess and LPS divisions contributed 80% and 20% of revenue, respectively. Bioprocess is housed in its subsidiary Sartorius Stedim Biotech, of which Sartorius AG has a 74% ownership and 85% voting control. The business is geographically diverse, with revenue across Europe, the Middle East, and Africa (37% of 2022 sales), the Americas (37%), and Asia-Pacific (26%). We estimate China revenue to be around 10%.

Sartorius AG Headlines

No Headlines